F-calprotectin and Blood Markers Correlate to Quality of Life in Pediatric Inflammatory Bowel Disease.
Our aim was to investigate predictors of health-related quality of life (HRQoL) with respect to changes in disease parameters over time in children with inflammatory bowel disease.



This was a prospective longitudinal study examining the association between HRQoL (IMPACT III) and symptom scores (Pediatric Crohn Disease Activity Index, abbreviated Pediatric Ulcerative Colitis Activity Index), fecal calprotectin measures and blood analyses (C-reactive protein, erythrocyte sedimentation rate, orosomucoid, albumin, hemoglobin, and vitamin-D) in a cohort of 10- to 17-year-old patients with inflammatory bowel disease. Data were collected prospectively at 3-month intervals during a 2-year period. Associations were analyzed using linear mixed-effect models. Patients were divided into 2 groups, which received nonbiological oral treatment or biological parenteral treatment.



From 79 patients (39 Crohn disease/40 ulcerative colitis), representing a total of 43,132 days of observation, 572 IMPACT measurements were paired with variables. A decrease in the IMPACT III score was significantly associated with increased ulcerative colitis-symptom score in the biological group (P = 0.005), and a similar inverse tendency was found in the nonbiological group and for Crohn disease symptoms in both groups. We found in both treatment groups overall a significant (P < 0.05) inverse association between the IMPACT III and the levels of fecal calprotectin, erythrocyte sedimentation rate, and orosomucoid, whereas albumin, hemoglobin, and vitamin-D were directly significantly associated.



The IMPACT score, already known to correlate with disease activity, has now been shown to be associated with disease markers in feces and blood. This emphasizes that objective markers of disease activity indirectly can predict the patient's HRQoL.
*Department of Pediatrics, Hvidovre Hospital, University of Copenhagen †Clinical Research Centre and Department of Orthopedics Surgery, Hvidovre Hospital, University of Copenhagen, Hvidovre ‡Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev §Department of Gastroenterology, Danish Centre for eHealth & Epidemiology, North Zealand Hospital, University of Copenhagen, Frederikssund, Denmark.
Katrine
K
Carlsen
Christian
C
Jakobsen
Thomas
T
Kallemose
Anders
A
Paerregaard
Lene B
LB
Riis
Pia
P
Munkholm
Vibeke
V
Wewer
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D002648:Child; D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D005243:Feces / Q000737:chemistry*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D039841:Leukocyte L1 Antigen Complex / Q000378:metabolism*; D008137:Longitudinal Studies; D008297:Male; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D005765:Gastrointestinal Agents; D039841:Leukocyte L1 Antigen Complex